Global Immuno-Oncology Diagnosis Market By Product & Service (Consumables, Instruments, Software), By Technology (PCR, NGS, Immunoassay), By Cancer Indications (Lung, Breast, Colorectal, Bladder, Melanoma), By Application (Research, Diagnostic), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2021-2031

An immuno-oncology diagnosis, also known as cancer immunotherapy, is a novel cancer therapy technique that harnesses the immune system’s power to control, stop, and kill cancer. Vaccines and allergy treatments are examples of immunotherapy, while immunotherapy in immune-oncology is used to specifically treat cancer. It’s a method of profiling analytes such as proteins, biomolecules, growth elements, cytokines, and chemokines by simultaneously detecting and measuring them.

In immuno-oncology, a test must distinguish between signals related to the presence or absence of a tumor immune response and signals connected with a tumor and normal tissue from a considerably broader signal input.

According to GLOBOCAN, cancer cases will rise to approximately 30 million by 2040 from 18 million in 2018. 70% of global cancer deaths occur in Africa, Asia, Central, and South America. Immunotherapy is the best treatment when other treatments don’t respond well, such as radiation and chemotherapy.

It helps other treatments work better and has more minor side effects than any other therapy. On the other hand, it causes adverse reactions such as swelling, itching, developing sores, redness, a stuffy head, and diarrhea. The drugs used in this therapy may harm other organs, and immunotherapy may take time to lead to optimal results.

Segmentation of the Global Immuno-Oncology Diagnosis Market:

By Product & Service

• Consumables
• Instruments
• Software

By Technology

• PCR
• NGS
• Immunoassay

By Cancer Indications

• Lung
• Breast
• Colorectal
• Bladder
• Melanoma

By Application

• Research
• Diagnostic

By Region

• North America
• Europe
• Asia-Pacific
• South America
• Middle East and Africa

Market Dynamics

The global immuno-oncology diagnosis market is expected to register increased revenue growth owing to an increase in R&D activities in pharmaceuticals for the treatment of cancer, as well as a surge in the incidence and prevalence rates of cancer, resulting in a need to conduct extensive research for diagnosis and treatment.

Furthermore, the increasing demand for biomarkers-based immuno-oncology therapy is anticipated to create more opportunities for the immuno-oncology market. Growing awareness levels concerning the early detection and treatment of cancers are also fueling the revenue growth of the immuno-oncology market.

Emerging nations are anticipated to offer potential expansion opportunities for global industry players due to technological advancements, booming geriatric populations that are more prone to seizure disorders, and the rolling-out of respective government initiatives towards the undertaking of research studies that are focused on immuno-oncology diagnosis.

However, major factors that may hinder market growth opportunities are high capital investments, the low cost-benefit ratio, as well as the shortage of skilled laborers.

Competitive Landscape

• Thermo Fisher Scientific Inc.
• Hoffmann-La Roche Ltd.
• Agilent Technologies Inc.
• Illumina Inc.
• Merck Millipore
• NanoString Technologies
• Sartorius AG
• HTG Molecular Diagnostics Inc.
• QIAGEN N.V.
• Invivoscribe Inc.
• Guardant Health Inc.

Recent Developments in this Industry:

• In July 2020, HTG Molecular Diagnostics Inc. (US) launched its HTG EdgeSeq Pan B-Cell Lymphoma Panel.
• In August 2019, Agilent Technologies Inc. (US), along with The National University of Singapore (NUS) and the National University Hospital (NUH), established Singapore’s first integrated translational R&D hub that leverages biochemical innovation and research data analytics to develop new methods of translating clinical research into clinical diagnostics.
• In May 2018, Invivoscribe Inc. (US) partnered with the American University of Beirut Medical Center (Lebanon) to establish a new center of excellence facility in the Middle East. This facility provides testing for all hematologic diseases, including leukemia and lymphoma.

For the Immuno-Oncology Diagnosis Market research study, the following years have been considered to estimate the market size: